BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12569595)

  • 1. Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
    Haese A; Chaudhari M; Miller MC; Epstein JI; Huland H; Palisaar J; Graefen M; Hammerer P; Poole EC; O'Dowd GJ; Partin AW; Veltri RW
    Cancer; 2003 Feb; 97(4):969-78. PubMed ID: 12569595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of prostate carcinoma stage by quantitative biopsy pathology.
    Veltri RW; Miller MC; Partin AW; Poole EC; O'Dowd GJ
    Cancer; 2001 Jun; 91(12):2322-8. PubMed ID: 11413521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
    Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
    Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma.
    Haese A; Epstein JI; Huland H; Partin AW
    Cancer; 2002 Sep; 95(5):1016-21. PubMed ID: 12209685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.
    Steuber T; Karakiewicz PI; Augustin H; Erbersdobler A; Lange I; Haese A; Chun KH; Walz J; Graefen M; Huland H
    J Urol; 2005 Mar; 173(3):737-41. PubMed ID: 15711259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Chun FK; Suardi N; Capitanio U; Jeldres C; Ahyai S; Graefen M; Haese A; Steuber T; Erbersdobler A; Montorsi F; Huland H; Karakiewicz PI
    Eur Urol; 2009 Mar; 55(3):617-28-6. PubMed ID: 18499335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
    Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
    Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma.
    Kattan MW; Stapleton AM; Wheeler TM; Scardino PT
    Cancer; 1997 Feb; 79(3):528-37. PubMed ID: 9028364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage.
    Veltri RW; Chaudhari M; Miller MC; Poole EC; O'Dowd GJ; Partin AW
    Clin Chem; 2002 Oct; 48(10):1828-34. PubMed ID: 12324513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.